新铍针治疗原发性骨质疏松性膝痛的临床疗效观察  

Clinical Curative Effect Observation on Treating Pain in Knee of Primary Osteoporosis Patients with New Beryllium Needle

作　　者：张晓宇[1] 刘爱峰[1] 张君涛[1] 杨莹[1] 张超[1] 张宇[1] 张玉亮 巩树伟 王平[1] ZHANG Xiao-yu;LIU Ai-feng;ZHANG Jun-tao(Department of Orthopedics,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin(300381),China)

机构地区：[1]天津中医药大学第一附属医院骨伤科,天津300381 [2]天津中医药大学,天津301617

出　　处：《中国中西医结合外科杂志》2020年第4期719-723,共5页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

基　　金：国家中医药管理局区域中医(骨伤科)诊疗中心;王平劳模创新工作室-天津市教委资助项目(津教工〔2016〕3号);天津市教委科研计划项目(2018KJ040);天津市卫生和计划生育委员会中医、中西医结合科研专项课题(2017118);天津中医药大学第一附属医院“拓新工程”基金科研课题(201912)。

摘　　要：目的:探讨新铍针治疗原发性骨质疏松性膝痛的临床疗效。方法:选取2017年3月—2019年3月天津中医药大学第一附属医院骨伤科收治的原发性骨质疏松伴有膝关节疼痛患者60例,随机分为对照组和观察组,各30例。对照组予以碳酸钙D3片、骨化三醇胶丸、鲑降钙素鼻喷雾剂。观察组在对照组的基础上采用新铍针结合拔罐治疗,两组均连续治4周。分别于治疗前后比较两组的VAS评分、BPI评分、Lequesne评分、患肢红外热成像温度的变化情况,并依据WOMAC骨关节炎指数进行疗效评价。结果:治疗后观察组和对照组VAS评分、BPI评分和Lequesne评分较治疗前降低,治疗后观察组VAS评分、BPI评分和Lequesne指数分别为3.03±0.72、23.50±1.20、5.63±0.96,显著低于对照组的5.20±0.76、37.77±1.17、7.73±0.83,差异有统计学意义(P<0.001)。观察组的WOMAC指数疗效改善率为93.33%,高于对照组的73.33%,差异有统计学意义(P<0.05)。患肢红外热成像温度临床疗效明显优于对照组,差异有统计学意义(P<0.05)。结论:新铍针治疗原发性骨质疏松性膝痛的疗效显著,操作简便,安全可行。Objective To observe the influence of new beryllium needle on treatment of pain in knee patients with primary osteoporosis.Methods Sixty primary osteoporosis patients were randomly divided into two groups with 30 patients in each group.All the patients were treated with calcium carbonate,calcitriol soft capsules and calcitonin(salmon)nasal spray.The patients in treatment group were treated with new beryllium needle combined with cupping therapy based on the above treatment.The visual analog scale(VAS)score,BPI score,WOMAC score,Lequesne score and the change of temperature in the infrared thermal imaging of the affected limb before treatment and in the 4 th week after treatment were analyzed.Results The differences in VAS score,BPI score and Lequesne score of the two groups which given before and after treatment was significant(P<0.001).The VAS score(3.03±0.72),BPI score(23.50±1.20),Lequesne score(5.63±0.96)of the observation group after treatmentwere significantly lower than those in the control group,which are(5.20±0.76),(37.77±1.17),and(7.73±0.83)respectively.The improvement rate in clinical impression of WOMAC score was 93.33%in observation group,while in control group was 73.33%(P<0.05).The change of temperature in the infrared thermal imaging of the affected limb in the observation group was better than that in the control group(P<0.05).Conclusion New beryllium needle has a clinical effect on improving pain in knee and daily independent ability of patients.It can be an effective method of traditional Chinese medicine therapy in the treatment of primary osteoporosis.

关 键 词：原发性骨质疏松 膝痛 新铍针疗法 

分 类 号：R681.55[医药卫生—骨科学]